Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports

Rahul P. Patel***, Madhur D. Shastri?, Long Chiau Ming†,∗,4, Syed Tabish R. Zaidi† and Gregory M. Peterson†

1 Pharmacy, School of Medicine, University of Tasmania, Hobart, TAS, Australia, 2 School of Health Sciences, University of Tasmania, Launceston, TAS, Australia, 3 School of Pharmacy, KPU Healthcare University College, Nilai, Malaysia, 4 Vector-borne Diseases Research Group (VERDI), Pharmaceutical and Life Sciences CoRe, Universiti Teknologi MARA, Shah Alam, Malaysia

Lichen planus (LP) is an uncommon mucocutaneous inflammatory condition, that is immunologically mediated, typically pruritic and often recurs. The currently advocated therapies are either not highly effective or associated with severe side effects. Enoxaparin, a widely used anticoagulant, is composed of both anticoagulant and non-anticoagulant fragments. Enoxaparin is reported to have anti-inflammatory properties and it was found to be effective in LP. However, the results from clinical studies have varied substantially and, therefore, the clinical role of enoxaparin in LP remains uncertain. This review focuses on potential reasons for the reported inconsistent outcomes, as well as proposing solutions; these include identifying batch-to-batch inconsistency in the composition of enoxaparin. The potential therapeutic value of enoxaparin in LP must be explored using well-designed clinical trials, combined with experimental studies that focus on identifying the anti-inflammatory fragments of enoxaparin and elucidating the mechanism of action of these non-anticoagulant fragments.

Keywords: anti-inflammatory, batch-to-batch variation, chromatography, enoxaparin, heparin, lichen planus, non-anticoagulant, response

INTRODUCTION

Lichen planus (LP) is a mucocutaneous inflammatory condition that can present with a variety of clinical manifestations. It mainly affects the skin, nails, scalp, and oral and genital mucous membranes. It is characterized by itchy, purplish, polygonal, flat-topped papules with lacy white lines (Wickham’s striae) (Gorouhi et al., 2014; Weston and Payette, 2015). The precise prevalence of LP is unknown but is estimated to be between 0.22 and 5% worldwide (Gorouhi et al., 2014). It can be associated with hepatitis C viral infection (Shengyuan et al., 2009). Without therapy, the skin lesions usually resolve over 6–18 months, although in up to 20% of patients relapse occurs in the same area as the initial episode (Gorouhi et al., 2014). Chronic disease is more likely with oral LP.

The etiology of LP is yet to be fully understood, but an immunological abnormality is believed to play an important role, notably involving antigen-presenting cells. Evidence so far suggests that LP is associated with T-cell mediated inflammation, in particular increased expression of heparanase and activation of keratinocytes (Daoud and Pittelkow, 2012). Patients with LP are reported to have elevated levels of several inflammatory mediators (tumor necrosis factor alpha (TNF-α),
interleukin (IL)-2, IL-4, IL-6, IL-10 and basic fibroblast growth factor), correlating with the severity of the condition (Simark-Mattsson et al., 1999; Pezelj-Ribaric et al., 2004; Gorugantula et al., 2012; Kaur and Jacobs, 2015). These inflammatory mediators stimulate the accumulation of T cells in the epidermis, ultimately resulting in destruction of the epidermis, referred to as a lichenoid tissue reaction.

A wide range of therapeutic approaches, including topical, systemic and intraleisonal corticosteroids, antihistamines, calcineurin inhibitors (e.g., cyclosporine, pimecrolimus, sirolimus, and tacrolimus), sulfasalazine, systemic and topical retinoids, aloe vera, and extracorporeal photo-chemotherapy, has been used for the treatment of the various forms of LP (Farhi and Dupin, 2010). However, the lack of evidence for efficacy of the currently advocated pharmacological agents, as well as their potential for significant side effects, can make the treatment frustrating for both clinicians and patients (Farhi and Dupin, 2010). Therefore, the search for safer and more effective modalities for the management of LP continues. Enoxaparin, a type of glycosaminoglycan, has attracted much interest among researchers due to its reported anti-inflammatory properties.

**ENOXAPARIN**

Enoxaparin, the first low-molecular-weight heparin (LMWH) approved by the Food and Drug Administration, has an average molecular weight of 4500 Da. Enoxaparin has largely replaced unfractionated heparin in clinical practice due to its fewer side effects, higher anti-factor (AFXa) activity and more predictable dose-response relationship (Dekker et al., 2016). As shown in Figure 1A, it is a highly negatively charged linear polysaccharide composed of repeating disaccharide units of D-glucosamine and uronic acid linked by 1→4 glycosidic bonds (Perkins et al., 2014). Enoxaparin is obtained by controlled chemical eliminative cleavage of the benzyl ester of heparin with alkaline treatment. This process results in the formation of LMW chains, of which typically 15–25% contain a 1,6-anhydroglucosamine at the reducing end (Figure 1B) (Perkins et al., 2014).

**Non-anticoagulant Fragments of Enoxaparin and Inflammation**

Enoxaparin is known to have a wide range of biological activities. It is a mixture of highly negatively charged, structurally complex fragments (dp2 – two saccharides to approximately dp22 – twenty two saccharides) with undefined structure and inherent variability. Enoxaparin possesses both anticoagulant and non-anticoagulant fragments, with substantial evidence that the latter fragments are accountable for the reported anti-inflammatory effects of enoxaparin. For example, in an in vitro study, lung epithelial cells were stimulated to release two inflammatory cytokines, IL-6 and IL-8. Stimulated cells were treated with either enoxaparin or its various fragments. The disaccharide fragments (dp2) without anticoagulant activity were found to be responsible for the anti-inflammatory effect of enoxaparin. In another study, peripheral blood mononuclear cells from patients with allergic inflammation were activated in the presence or absence of enoxaparin fragments before measuring the levels of inflammatory cytokines (Shastri et al., 2015c). Two fragments of enoxaparin without anticoagulant activity were found to be responsible for the inhibition of cytokine secretion. A disaccharide fragment (dp2) inhibited the release of IL-4, IL-5, IL-12, and TNF-α by more than 57%, while a tetrasaccharide fragment (dp4) inhibited the release of these cytokines by 68%.

Lean et al. (2014) identified various fragments of enoxaparin with pro- and anti-proliferative effects. The authors treated the human colonic epithelial cancer cells in the presence of enoxaparin or its various fragments. Interestingly, the smallest fragment of enoxaparin (dp2), devoid of any anticoagulant activity, showed the strongest anti-proliferative effect (Lean et al., 2014). Shastri et al. (2013) investigated the ability of enoxaparin-derived fragments to inhibit nitric oxide production by lipopolysaccharide-activated macrophages. The disaccharide fragment of enoxaparin did not exhibit any anticoagulant activity but it reduced the production of nitric oxide by 50%. In a

---

**FIGURE 1** | The disaccharide contains two residues of uronic acid and d-glucosamine linked by a 1→4 glycosidic linkage (A). Approximately 15–25% of enoxaparin oligosaccharides contain 1,6-anhydro groups at their reducing end (B) as a result of chemical b-eliminative cleavage of unfractionated heparin. Reproduced with permission (Patel et al., 2009c).
preclinical study, male C57BL/6 mice with chemically induced intestinal inflammation were treated with various fragments of enoxaparin. The tetrasaccharide fragments (dp4) of enoxaparin prevented the increase of relative colon weight, and the hexasaccharides (dp6) selectively reduced shortening of the colon (Lean et al., 2016). The authors reported that the identified active tetrasaccharides did not exert anticoagulant activity and the hexasaccharides had a low risk of bleeding, as the measured anticoagulant activity was reduced 10-fold compared to parent enoxaparin.

Clinical Use of Enoxaparin in LP

Topical and intralesional corticosteroids are the current first-line therapy for LP (Lebwohl et al., 2017). However, large scale randomized clinical trials are still warranted to establish the efficacy of corticosteroids, as well as other available modalities for different variants of LP (Atzmony et al., 2016). At present, drug treatments for LP are either not completely effective and/or associated with severe side effects (Atzmony et al., 2016). LP can be chronic and relapsing in nature, and is often resistant to the currently available pharmacological agents. Therefore, the search for more effective and safer therapeutic agents for the treatment of LP continues.

Enoxaparin is the only derivative of heparin that has been so far evaluated for its clinical efficacy in LP. The studies have reported mixed but encouraging clinical outcomes. Ingber et al. (1994) demonstrated that low subcutaneous doses of enoxaparin inhibited the elicitation of allergic contact dermatitis. This preliminary finding led to the investigation of enoxaparin in 11 patients with histopathologically proven LP (Hodak et al., 1998). Subcutaneous injection of 3 mg of enoxaparin once-weekly for either 4 or 6 weeks resulted in complete regression of the eruption, with residual post-inflammatory hyperpigmentation in more than 70% of patients (8 out of 11). On the basis of these encouraging early findings, the potential role of enoxaparin in LP was further explored by researchers internationally.

To date, one randomized clinical trial, and twelve small, open-labeled and non-randomized clinical studies have investigated the therapeutic efficacy of subcutaneously administered enoxaparin in LP (Table 1). Stefanidou et al. (1999) evaluated the efficacy of enoxaparin in 18 patients with various types of LP and reported complete remission in 61% of patients and marked improvement in a further 11%. Similarly, Pacheco and Kerdel (2001) reported marked improvement in 5 out of 7 patients with LP when treated with enoxaparin. In another study, patients with LP were treated with enoxaparin for 4–14 weeks and 21 of 24 patients achieved complete remission (Akdeniz et al., 2005). Similarly, once-weekly use of enoxaparin over a period of 20 weeks resulted in a dramatic improvement in visual analog scale assessments of pain and itch in 13 out of 15 patients unresponsive to topical or oral corticosteroid therapy (Ameen and Alfadhily, 2011). Yasar et al. (2011) reported complete remission of palmoplantar hyperkeratotic LP (HPLP), a relatively uncommon form of LP that is mostly resistant to conventional treatments, in 2 patients treated with enoxaparin for 3 months (Yasar et al., 2011). No recurrence of PHLP was noted in follow-ups performed over a period of 1 year. Khan et al. (2014) treated cutaneous LP with enoxaparin for 6 weeks. They reported disease improvement in 26 out of 31 patients. Uçmak and co-workers reported distinctive recovery of the disease in 71% of patients (15 out of 21) treated with enoxaparin for 12 weeks (Uçmak et al., 2012). Neville et al. (2007) demonstrated a sustained clinical response to enoxaparin in a patient with recalcitrant ulcerative LP resistant to oral corticosteroids. All of the reports above used 3 mg of subcutaneous enoxaparin once-weekly and reported that the therapy was well tolerated and was not associated with any major side effects.

However, some clinical studies have shown disappointing results. For example, 3 mg subcutaneous enoxaparin was administered once-weekly for a period of 6 weeks to 10 patients with proven LP (with or without oral lesions) (Rai et al., 2002). None of the patients showed clinical remission at the end of the study. Side effects, such as skin necrosis or multiple lesions with increased itching, were observed in 20% of patients not allergic to enoxaparin, heparin, or its derivatives. The observed side effects were severe enough to require discontinuation of enoxaparin. Ferahbas et al. (2003) presented a study in which 7 patients with histologically proven LP were treated with 5 mg of subcutaneous enoxaparin once-weekly for 6 weeks. Mild clinical improvement was observed in only 1 patient and the other 6 patients did not show improvement.

Another study compared the efficacy and safety of methotrexate and enoxaparin in patients with generalized LP, with a 6-month follow up (Lunge et al., 2016). Although 5 mg of subcutaneous enoxaparin administered once weekly for 16–24 weeks produced remission of skin lesions in 13 out of 20 patients, 35% of patients showed relapse after discontinuation of enoxaparin. The authors concluded that methotrexate was not only more effective in terms of causing complete remission of the disease, but also better tolerated and associated with a lower recurrence rate than enoxaparin. An open-labeled, uncontrolled study treated 37 cases of cutaneous LP with 3 mg of enoxaparin once-weekly for 6 weeks. Complete remission was not observed in any of the patients and the reported side effects were local irritation, bruises and headache (Khan et al., 2014). So far, only one randomized clinical trial investigated the efficacy of enoxaparin in patients with disseminated LP (Iraji et al., 2013). In this study, 25 patients were treated with 5 mg of subcutaneous enoxaparin once-weekly for 8 weeks, and 23 patients with 0.5 mg/kg daily oral prednisolone until complete remission was observed or for a maximum of 8 weeks. The reported therapeutic response rate was statistically lower for enoxaparin (32% complete remission) than oral prednisolone (69.6% complete remission). However, the number of patients with reported side effects were non-statistically fewer in the enoxaparin group than the prednisolone group.

PROPOSED REASONS FOR REPORTED INCONSISTENT CLINICAL OUTCOMES

It is important to note that heparins, including LMWHs such as enoxaparin, have shown inconsistent outcomes when used in other clinical conditions where a non-anticoagulation effect is
| Author          | Year | Study design | Patients                                                                 | No. of patients | Enoxaparin dose/duration | Previous treatment                                                                 | Clinical effect                                                                                                                                                                                                 | Side effects |
|-----------------|------|--------------|--------------------------------------------------------------------------|-----------------|--------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Hodak et al.    | 1998 | Pilot        | Histopathologically proven LP with intense pruritus for 2-36 months. One patient had palmoplantar involvement and 4 had oral lesions | 10              | 3 mg once weekly for 4 or 6 weeks | Topical corticosteroids and oral H1 blockers                                      | Eight patients achieved a complete remission; one patient had marked clinical improvement; no clinical effect was observed in one patient | No side effects were observed |
| Stefanidou et al. | 1999 | Open-label   | Hypertrophic LP, disseminated LP, disseminated and reticular oral LP, localized LP, localized and reticular oral LP, erosive oral LP, or disseminated and erosive oral LP | 18              | 3 mg once weekly for 6-13 weeks | Topical corticosteroids and/or systemic corticosteroids and/or cyclosporine and/or retinoids | 11 of 18 patients achieved a complete remission; two achieved marked improvement; 5 patients showed no change | No side effects were observed |
| Pacheco and Kerdel | 2001 | Case series | Oral LP, lichen planopilaris, erosive genital LP, generalized eruptive LP | 7               | 30 mg once a day for 6 months or once a week for 4, 6, or 12 weeks or once every other day for 1 or 4 months or once a week for 10 weeks | Topical and/or systemic corticosteroids                                               | 5 of 7 patients experienced a marked improvement and 2 patients had no clinical improvement                                                                 | No side effects were observed |
| Rai et al.      | 2002 | Open-label   | Histopathologically proven LP with or without associated oral lesions    | 10              | 3 mg once weekly for 6 weeks | Previously untreated patients                                                     | Complete remission was not seen in any patients. Clinical response was seen in only 2 of 10 patients                                                                 | 1 patient developed skin necrosis after the 4th injection and one patient developed multiple lesions over both lower and upper extremities with increased itching after the fourth injection |
| Ferahbas et al. | 2003 | Open-label   | Histopathologically proven disseminated LP, disseminated with papular LP, localized LP, localized with papular LP, hypertrophic LP or localized with hypertrophic LP | 7               | 5 mg once a week for 6 weeks | Topical and/or systemic corticosteroids, PUVA, sedatives and systemic anti-histamines | 6 of 7 patients had no histological changes. 5 of 7 patients had no clinical improvement and itching decreased in 2 patients | No side effects were observed |
| Akdeniz et al.  | 2005 | Open-label   | Histopathologically proven LP with intense pruritus. Patients had either disseminated, disseminated with reticulated oral LP or hypertrophic LP | 24              | 3 mg once a week for maximum 14 weeks | Topical and/or systemic corticosteroids                                               | 20 of 24 patients achieved a complete remission and 4 patients had no or minimal clinical effect                                                                 | No side effects were observed |
| Author          | Year  | Study design         | Patients                          | No. of patients | Enoxaparin dose/duration | Previous treatment | Clinical effect                                                                                     | Side effects                                           |
|-----------------|-------|----------------------|-----------------------------------|-----------------|--------------------------|---------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Neville et al.  | 2007  | Case study           | Patient with ulcerative LP and hepatitis C | 1               | 30 mg biweekly for the first 2 weeks and then 3 mg biweekly for the next 4 weeks | Topical corticosteroid and topical immunosuppressant | Complete remission of the lesions and the patient was in remission for 18 months. A slight flare of LP on the palm was developed later on which was controlled with topical treatment of corticosteroids and immunosuppressant | No side effects were observed                         |
| Ameen and Alfadily | 2011  | Open-label           | Patients with recalcitrant LP     | 15              | 3 mg once a week for a period of 20 weeks | Topical and systemic corticosteroids | 2 of 15 patients with mild form of LP had complete remission of the lesions. 13 of 15 patients with moderate or severe LP did not achieve complete remission. 13 of 15 patients reported significant reduction in itching | No side effects were observed                         |
| Yasar et al.    | 2011  | Case series          | Palmoplantar hyperkeratotic variant of LP | 2               | 3 mg once a week for 12 weeks | Not specified | Skin lesions were healed in both the patients but oral mucosal lesions remained stable | No side effects were observed                         |
| Ucmak et al.    | 2012  | Open-label           | LP - Type of LP not specified     | 2               | 3 mg once a week for 12 weeks | Systemic or local treatment - pharmacological agent not specified | 15 of 21 patients showed perfect recovery and 4 out of 21 patients showed distinct recovery. The terms “perfect recovery” and “distinct recovery” were not defined by the authors | No side effects were observed                         |
| Khan et al.     | 2014  | Open-label           | Cutaneous LP                      | 37              | 3 mg once a week for 6 weeks | Not specified | Improvement in papular eruption, scaly lesions and pigmentation; Complete remission was not observed in any of the enoxaparin-treated patients | No side effects were observed                         |
| Iraji et al.    | 2013  | Multicentre randomized clinical study | Disseminated LP                  | 25              | 5 mg once a week until complete remission or a maximum of 8 weeks | Not specified | 8 (32%) patients had complete remission, 10 (40%) patients had partial improvement and 7 patients (28%) had no improvement | No side effects were observed in 24 patients and one patient suffered from a rash of new lesions at the injection site |
| Lunge et al.    | 2016  | Non-randomized controlled clinical study | Generalized LP                   | 20              | 5 mg once a week for 16 to 24 weeks | Topical corticosteroid, antihistamines or emollients | 13 patients had complete remission of skin lesions. However, 7 patients showed relapse after discontinuation of enoxaparin | No side effects were observed                         |
required. For example, so far 19 clinical studies have investigated the efficacy of heparin or its low molecular weight derivatives in ulcerative colitis (UC), a chronic inflammatory condition (Lean et al., 2015). Some studies reported a significant clinical improvement while others have shown little or no clinical benefit of heparins in this condition. Brazier et al. reported complete remission in 4 of 6 patients with UC when treated with heparin (Brazier et al., 1996). Similarly, 12 out 16 patients with severe refractory UC treated with either intravenous or subcutaneous heparin showed significant clinical improvement (Evans et al., 1997). On the other hand, several randomized studies have reported no clinical benefit of heparin over placebo when used for the management of mild-to-moderate UC (Lean et al., 2015).

One study showed that heparin has an inhibitory effect on methacholine-induced bronchoconstrictive response and, therefore, could potentially be used for the management of asthma (Ceyhan and Celikel, 1995). However, in another study such an effect of heparin was not observed (Pavord et al., 1996).

The possible reasons behind the observed discrepancies in the reported clinical outcomes when enoxaparin was used for the management of LP are briefly discussed below.

**Variable Study Designs**

The duration and the dosage regimen of the treatment, and sub-type and severity of the disease could affect the response. For example, clinical studies so far investigating the potential of enoxaparin in LP included the use of: (i) different treatment durations (ranging from 4 to 24 weeks); (ii) different dosage regimens of enoxaparin (e.g., 3 mg once-weekly for 6 weeks or 5 mg once-weekly for 24 weeks, or 30 mg bi-weekly for the first 2 weeks and then 3 mg bi-weekly for the next 4 weeks); (iii) different disease extent and severity (mild, moderate, severe, active or refractory LP); (iv) different forms and types of LP (cutaneous, ulcerative, disseminated, generalized, recalcitrant, localized, hypertrophic, palmoplantar etc.); and (v) inconsistent study end points (remission of disease symptoms, self-reported visual analog scales, histologic improvement etc.). Apart from these explanations, the reported inconsistent clinical outcomes could be due to the (i) use of sub-therapeutic dose of enoxaparin and/or (ii) presence of compositional variation in different batches of enoxaparin.

**Use of Sub-Therapeutic Dose of Enoxaparin**

In clinical practice, enoxaparin is normally used for the prevention and treatment of venous thromboembolic disorders, including deep vein thrombosis and pulmonary embolism. The prophylactic dose of enoxaparin in patients with a low-to-moderate risk of venous thromboembolism is 20 mg once daily by subcutaneous injection. For the treatment of venous thromboembolism, the recommended dose of enoxaparin in a 60 kg patient is 90 mg once daily. All the studies, except one, investigating the role of enoxaparin in LP used the dose of either 3 or 5 mg once-weekly (Table 1). An earlier report of the successful use of 3 mg subcutaneous enoxaparin in contact dermatitis (Ingber et al., 1994), a T-cell driven inflammatory condition, triggered the use of the same dose in subsequent studies in patients with LP, also a T-cell mediated autoimmune disease.

Plasma concentrations of enoxaparin after 20 and 40 mg subcutaneous administration are reported to be 1.6 and 3.8 µg/mL, respectively (Sanofi-Aventis Australia Pty Ltd., 2014). Enoxaparin, in various in vitro, in vivo and ex vivo studies, displayed its anti-inflammatory activities at concentrations much higher than its plasma concentrations required to achieve an anticoagulant effect. For example, an in vivo study testing the individual non-anticoagulant fragments of enoxaparin for their anti-inflammatory effects used the dose that corresponded to the amount of each fragment present in intact enoxaparin (Lean et al., 2016). The authors reported that the doses for non-anticoagulant fragments were found to be significantly lower than the doses required for their anti-inflammatory effect. In another study, a LMWH was found to be more effective than placebo for treating patients with UC when administrated by extended colon-release tablets (Chande et al., 2010). However, the same benefits were not seen when a LMWH was administered subcutaneously in lower doses (Chande et al., 2010). The immunological activity in LP correlates with the disease severity and the low doses of enoxaparin used in previous studies to treat various forms of LP may not be sufficient to elicit an optimal clinical effect.

**Batch-to-Batch Inconsistency**

The reported variable clinical efficacy of enoxaparin when used for the treatment of LP could be because of the batch-to-batch inconsistency in the enoxaparin formulation. Batch-to-batch inconsistency could result in compositional differences between fragments potentially responsible for the anti-inflammatory effects of enoxaparin. The commercially available enoxaparin is standardized only according to the anti-coagulant activity; it is not standardized for the non-anticoagulant fragments. The authors hypothesized that the compositional differences between batches of enoxaparin manufactured by the same manufacturer could result in batch-to-batch variations in the presence of these fragments. Patel et al. (2008) developed a capillary electrophoresis method for fingerprinting batches of commercially available enoxaparin. Surprisingly, the method clearly revealed six compositional differences in two different batches of enoxaparin.

The initial study that examined the effects of enoxaparin in LP reported complete regression of the eruption in eight out of the ten patients (Hodak et al., 1998). However, similar outcomes were not observed in some subsequent studies, and it was previously hypothesized that the compositional differences between batches of enoxaparin may be responsible for the inconsistent observations (Ferahbas et al., 2003; Akdeniz et al., 2005).

**POSSIBLE SOLUTIONS TO AVOID INCONSISTENT CLINICAL OUTCOMES**

**Determination of Clinical Efficacy of Non-anticoagulant Fragments in LP**

We believe that the ideal solution is to obtain non-anticoagulant fragments of enoxaparin, and examine the efficacy of each
fragment against LP. There are two principal approaches of obtaining non-anticoagulant fragments of enoxaparin. One approach is through enzymatic or chemical digestion of enoxaparin. Digestion processes, otherwise known as depolymerisation, are often carried out at elevated temperatures. The sulfation pattern of enoxaparin’s fragments is important for the various non-anticoagulant activities (Wang, 2011; Shastri et al., 2015c). At elevated temperatures, some of the fragments undergo desulfation resulting in structural changes and potential loss of their biological activity (Patel et al., 2009c). Enoxaparin undergoes aggregation at low temperatures resulting in the loss of its biological activity (Patel et al., 2009b). Digestion processes also involve freeze-drying and, therefore, the fragments of enoxaparin obtained after digestion may be structurally and therapeutically different from the fragments prior to the digestion process.

Another approach to obtain various fragments of enoxaparin is through chromatographic techniques. Enoxaparin is difficult to separate into its various fragments due to its high polarity, negative charge and structural complexity. However, various chromatographic techniques, such as capillary electrophoresis (Patel et al., 2008), reversed-phase high-performance liquid chromatography (Patel et al., 2009a) and, more recently, ion-exchange chromatography have been developed and validated for the separation of enoxaparin into its fragments (Shastri et al., 2013). The later chromatographic technique successfully separated enoxaparin into more than 20 various fragments without prior chemical or enzymatic digestion of parent enoxaparin. Using the same technique, other studies have identified groups of fragments in enoxaparin with high, low and no anticoagulant activity (Lean et al., 2015, 2016; Shastri et al., 2015c). In addition, Shastri et al. (2013) demonstrated the anti-inflammatory effect of enoxaparin fragments separated through ion-exchange chromatography.

The therapeutic effect of each non-anticoagulant fragment obtained through chromatographic techniques should first be investigated using preclinical animal models of LP. The preclinical testing of non-anticoagulant fragments using an animal model to determine the fragments responsible for the efficacy of enoxaparin in LP is not a prerequisite before evaluating such fragments in humans. However, apart from providing information such as therapeutic efficacy and safety parameters essential to design a clinical study, a preclinical study would provide the dose-response relationship for each non-anticoagulant fragment. It is important to note that all the studies so far looking at the efficacy of enoxaparin in LP have admittedly employed doses that were sub-therapeutic for anticoagulant activity to minimize the risk of bleeding. However, as previously noted, the anti-inflammatory activities of heparin are expressed at higher concentrations, where anticoagulant effects and hence bleeding predominate if anticoagulant fragments are administered. The information on dose-response relationship is crucial as enoxaparin’s fragments have shown dose-dependent anti-inflammatory effects in ex vivo and in vitro studies (Shastri et al., 2013, 2015b). Enoxaparin is composed of multiple fragments containing the same number of saccharides. For example, enoxaparin contains approximately 6 fragments that are composed of four saccharides (dp4) (Shastri et al., 2013). The relative percentile amount of one of the six dp4 fragments in 500 µg/mL of enoxaparin is approximately 5% (2.5 µg/mL). This fragment, when used at 2.5 µg/mL, was not able to inhibit different types of inflammatory cytokines released from activated human immune cells. However, at 20 µg/mL, the same fragment inhibited the release of IL-4, IL-5, IL-13, and TNF-α by more than 69, 70, 75, and 70%, respectively (Shastri et al., 2015c).

Dose-response activity obtained from an animal model would provide much needed guidance on the likely appropriate dose of active fragments required to elicit therapeutic effects in patients with LP. Therefore, preclinical studies followed by clinical investigations may lead to a new formulation of enoxaparin fragments that exhibit anti-inflammatory properties, without significant anticoagulant activity. The development of such a formulation can therefore serve as a novel therapeutic approach for the treatment of LP. However, development and regulatory approval of such a formulation would require extensive validation and formulation steps that are likely to take a long time to eventuate.

Monitoring Batch-to-Batch Consistency

Until a novel formulation of non-anticoagulant fragments of enoxaparin is developed and subsequently approved by regulatory agencies and commercially available, studies of different doses of enoxaparin and with large number of patients will provide better insight into the effectiveness of this drug. A key aspect in determining the clinical efficacy of commercially available enoxaparin in LP is the necessity to maintain consistency in the non-anticoagulant fragments between different batches. The best possible way seems to be to obtain the standard chromatographic profiles of non-anticoagulant fragments of a particular batch of enoxaparin with a proven clinical value in LP. Other batches of enoxaparin could then be verified for the batch-to-batch uniformity by comparing the separation patterns of their non-anticoagulant fragments against the standard chromatographic profile.

WAY FORWARD

Efficacy of Other LMWHs in LP

Surprisingly, no study so far has investigated the efficacy of unfractionated heparin or LMWHs other than enoxaparin. LMWHs such as dalteparin, tinzaparin, nadroparin, fondaparinux, and reviparin are also approved anticoagulants. Dalteparin and enoxaparin have shown improved clinical outcomes when used for the management of UC (Torkvist et al., 1999; Dotan et al., 2001). On the other hand, no significant beneficial effect was observed with the use of tinzaparin or reviparin in patients with UC (Bloom et al., 2004; de Bievre et al., 2007).

Low-molecular-weight heparins are obtained by enzymatic degradation of heparin or through chemical processes. Currently
available LMWHs have different *in vitro* and *ex vivo* non-anticoagulant activities, physico-chemical characteristics and pharmacodynamics. These derivatives also differ in terms of their sulfation pattern, an important parameter for their non-anticoagulant activity, as well as their ability to interact with cellular proteins, endothelial cells and inflammatory cytokines (Prandoni, 2003).

Interestingly, in one study the observed effect of enoxaparin on the release of inflammatory cytokines was opposite to dalteparin (Shastri et al., 2015a,c). Enoxaparin inhibited cytokine release by more than 48%, whereas dalteparin increased their release by more than 25%. Smaller fragments were responsible for the inhibitory effect of enoxaparin and the larger fractions were associated with the stimulatory effect of dalteparin. Therefore, future studies should not only investigate the efficacy of other LMWHs in LP, but also compare the clinical effects of various LMWHs.

**Structural Elucidation of Active Non-anticoagulant Fractions of Enoxaparin**

It is estimated that only 30% of fragments in heparins are composed of the pentasaccharide sequence responsible for their anticoagulant activity. This pentasaccharide sequence selectively binds to anti-thrombin, resulting in enhanced effects of anti-thrombin on factor Xa. The structure of pentasaccharide sequence is shown in Figure 2. The fragments of enoxaparin that do not possess anticoagulant activity are reported to be responsible for heparin’s non-anticoagulant activity, including anti-inflammatory effect. Given the potential of enoxaparin in LP, future studies should aim for identification and structural elucidation of therapeutically active non-anticoagulant fragments. After identifying the fragments of enoxaparin and establishing dose-response relationships, their structural elucidation should be carried out using sophisticated techniques such as mass spectrometry and nuclear magnetic resonance. Once the structures of active fragments are established, structure-activity relationships should provide important information on the precise location and sulfation pattern required for the anti-inflammatory activity.

As a new formulation containing identified fragments would have been derived from commercially available enoxaparin, it may face patent and regulatory approval related complications. Elucidation of structure-activity relationships would enable the structural modification of identified fragments without compromising their clinical efficacy in LP. Such an approach would allow the synthesis of new compounds, structurally different from the active non-anticoagulant fragments of enoxaparin, without losing the anti-inflammatory effect. Using a similar approach, an ultra LMWH (known as fondaparinux) was developed and is currently used for the treatment of deep vein thrombosis and acute pulmonary embolism. Fondaparinux is a synthetic pentasaccharide devoid of other non-anticoagulant fragments present in various types of heparins. Therefore, it does not bind to various plasma proteins other than anti-thrombin.

**Mechanism of Action of Active Non-anticoagulant Fractions of Enoxaparin**

The mechanisms by which enoxaparin exerts its therapeutic effect in LP is currently unknown. Therefore, future research should investigate the possible mode of action of identified non-anticoagulant fragments of enoxaparin in LP. So far, only one study has investigated the possible mechanisms by which non-anticoagulant fragments of enoxaparin inhibited the release of inflammatory cytokines (Shastri et al., 2015a,c). In this study, the peripheral blood mononuclear cells were collected from asthmatic patients and then the cells were stimulated using lectins, such as phytohaemagglutinin and concanavalin A, in the presence or absence of various non-anticoagulant fragments of enoxaparin. The authors concluded that the potential mechanism by which the tested fragments suppressed the inflammatory response was through directly interacting with cell surface receptors and covering different signaling pathways. However, it remains to be seen if such inhibition is limited to stimulation of cells through plant
lectins or is extended to antigen-specific activation of the T cell receptor.

**CONCLUSION**

One of the important reasons for the observed inconsistent clinical outcomes when enoxaparin has been studied for the treatment of LP could be the presence of structurally different non-anticoagulant fragments in different batches of enoxaparin. Based on the available scientific evidence, the authors believe that enoxaparin may play an important role in the management of LP and its potential must be explored using well-designed clinical trials and experimental studies that focus on identifying the anti-inflammatory fragments of enoxaparin and elucidating the mechanism of actions and appropriate therapeutic doses of these non-anticoagulant fragments.

**REFERENCES**

Akdeniz, S., Harman, M., Atmaca, S., and Yaldiz, M. (2005). The management of lichen planus with low-molecular-weight heparin (enoxaparin). Int. J. Clin. Pract. 59, 1268–1271.

Ameen, W. A., and Alfadhily, Z. S. (2011). Treatment of recalcitrant lichen planus with low molecular weight heparin (Enoxaparin): a case series study among Iraqi patients. Med. J. Babylonon 8, 93–103.

Atzmony, L., Reiter, O., Hodak, E., Gdalevich, M., and Mimouni, D. (2016). Treatments for cutaneous lichen planus: a systematic review and meta-analysis. Am. J. Clin. Dermatol. 17, 11–22. doi: 10.1007/s40257-015-0160-6

Bloom, S., Kiilerich, S., Lassen, M. R., Forbes, A., Leiper, K., Langholz, E., et al. (2004). Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 19, 871–878.

Brazier, F., Yzet, T., Boruchowicz, A., Colombeb, J., Duchmann, J., and Dupas, J. (1996). Treatment of ulcerative colitis with heparin. Gastroenterology 110:A872.

Ceyhan, B., and Celikel, T. (1995). Effect of inhaled heparin on methacholine-induced bronchial hyperreactivity. Chest 107, 1009–1012.

Chande, N., Mcdonald, J. W., Macdonald, J. K., and Wang, J. J. (2010). Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 6:CD006774.

Daoud, M. S., and Pittelkow, M. R. (2012). “Lichen planus,” in Fitzpatrick’s Dermatology in General Medicine, 5th Edn, eds L. Goldsmith, S. Katz, B. Gilchrest, A. Paller, D. Leffell, and K. Wolff (New York, NY: McGraw-Hill Education), 561–577.

de Biere, M. A., Vrij, A. A., Schoon, E. J., Dijkstra, G., de Jong, A. E., and Oberndorff-Klein Woollthus, A. H. (2007). Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm. Bowel Dis. 13, 753–758.

Dekker, K. R., Myers, B. L., and Barras, M. A. (2016). Compliance with enoxaparin dosing and monitoring guidelines and the impact on patient length of stay: a pilot study. Ther. Drug Monit. 38, 59–63. doi: 10.1097/FTD.0000000000000233

Dotan, I., Hallak, A., Arber, N., Santo, M., Alexandrowitz, A., Knaani, Y., et al. (2001). Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig. Dis. Sci. 46, 2239–2244.

Evans, R. C., Wong, V. S., Morris, A. I., and Rhodes, J. M. (1997). Treatment of corticosteroid-resistant ulcerative colitis with heparin—a report of 16 cases. Aliment. Pharmacol. Ther. 11, 1037–1040.

Farhi, D., and Dupin, N. (2010). Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin. Dermatol. 28, 100–108. doi: 10.1016/j.clindermatol.2009.03.004

Ferahbas, A., Uksal, U., Kutlugun, C., and Kontas, O. (2003). Low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus. J. Eur. Acad. Dermatol. Venereol. 17, 604–605.

Gorouhi, F., Davari, P., and Fazel, N. (2014). Cutaneous and mucosal lichen planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis. ScientificWorldJournal 2014:742826. doi: 10.1155/2014/742826

Gorogantula, L. M., Rees, T., Plemons, J., Chen, H. S., and Cheng, Y. S. (2012). Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 114, 215–222. doi: 10.1016/j.orsur.2012.03.013

Hodak, E., Yosipovitch, G., David, M., Inger, A., Chorev, L., Lider, O., et al. (1998). Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J. Am. Acad. Dermatol. 38, 564–568.

Inger, A., Trattner, A., Cohen, I. R., and Mekori, Y. A. (1994). Low doses of low molecular weight heparin in vivo inhibits the elicitation of contact hypersensitivity. Acta Derm. Venereol. 74, 454–456.

Iraji, F., Asilian, A., Saeidi, A., Siadat, A. H., Saeidi, A. R., and Hassanzadeh, A. (2013). Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus: A clinical trial. Adv. Biomed. Res. 2:6. doi: 10.4103/2277-9175.115798

Kaur, J., and Jacobs, R. (2015). Proinflammatory cytokine levels in oral lichen planus. J. Armed Forces Med. Coll. Bangladesh 9, 2–7.

Lean, Q. Y., Gueven, N., Eri, R. D., Bhatia, R., Sohal, S. S., Stewart, N., et al. (2015). Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes. Expert Rev. Clin. Pharmacol. 8, 795–811. doi: 10.1586/17512433.2015.1082425

Lean, Q. Y., Patel, R. P., Stewart, N., Sohal, S. S., and Gueven, N. (2014). Identification of pro- and anti-proliferative oligosaccharides of heparins. Integr. Biol. 6, 90–99. doi: 10.1039/c3ib0206a

Lean, Q. Y., Gueven, N., Eri, R. D., Peterson, G. M., and Patel, R. P. (2016). “Non-Anticoagulant oligosaccharides of enoxaparin relieve chemical-induced acute colitis,” in Advances in Medicine and Biology, ed. L. V. Berhardt (New York, NY: Nova Science Publishers), 87–104.

Lebwohl, M. G., Heymann, W. R., Berth-Jones, J., and Coulson, I. (eds.) (2017). Treatment of Skin Disease: Comprehensive Therapeutic Strategies, 5th Edn (Philadelphia, PA: Elsevier Health Sciences), 441–444.

**AUTHOR CONTRIBUTIONS**

RP conceived and designed the review. RP and MS performed the literature search. RP, MS, LM, SZ, and GP analyzed the data and wrote the paper.

**FUNDING**

The study was partially funded by Research Entity Initiative: 600-IRMI/IRMI-REI (0004/2016), Universiti Teknologi MARA (UiTM), and Ministry of Higher Education. The authors would like to express their gratitude to the Ministry of Higher Education, Malaysia, Universiti Teknologi MARA, and KPJ Healthcare University College for the support rendered for this research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Lunge, S., Patil, S., and Manjunathswamy, B. (2016). A comparative study of methotrexate & low molecular weight heparin for the treatment of generalized lichen planus. Indian J. Clin. Exp. Dermatol. 2, 153–158.

Neville, J. A., Hancock, J. G., Williford, P. M., and Yosipovitch, G. (2007). Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C. Cutis 79, 37–40.

Patel, R. P., Narkowicz, C., Hutchinson, J. P., Hilder, E. F., and Jacobson, G. A. (2008). A simple capillary electrophoresis method for the rapid separation and determination of intact low molecular weight and unfractionated heparins. J. Pharm. Biomed. Anal. 46, 30–35.

Patel, R. P., Narkowicz, C., and Jacobson, G. A. (2009a). Effective reversed-phase ion pair high-performance liquid chromatography method for the separation and characterization of intact low molecular weight heparins. Anal. Biochem. 387, 150–157. doi: 10.1016/j.ab.2009.01.007

Patel, R. P., Narkowicz, C., and Jacobson, G. A. (2009b). Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution. J. Pharm. Sci. 98, 1118–1128. doi: 10.1002/jps.21483

Patel, R. P., Narkowicz, C., and Jacobson, G. A. (2009c). Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin. J. Pharm. Sci. 98, 1700–1711. doi: 10.1002/jps.21556

Pavorud, I., Mudassar, T., Bennett, J., Wilding, P., and Knox, A. (1996). The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Eur. Respir. J. 9, 217–219.

Perkins, S. J., Fung, K. W., and Khan, S. (2014). Molecular interactions between complement factor H and its heparin and heparan sulfate ligands. Front. Immunol. 5:126. doi: 10.3389/fimmu.2014.00126

Pezelj-Ribaric, S., Prso, I. B., Abram, M., Glazar, I., Brumini, G., and Simunovic-Soskic, M. (2004). Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Arch. Oral Biol. 49, 131–133.

Prandoni, P. (2003). Low molecular weight heparins: are they interchangeable? Yes. J. Thromb. Haemost. 1, 10–11.

Rai, R., Kaur, I., and Kumar, B. (2002). Low-dose low-molecular-weight heparin in lichen planus. J. Am. Acad. Dermatol. 46, 141–143.

Shastri, M. D., Stewart, N., Horne, J., Peterson, G. M., Gueven, N., Sohal, S., et al. (2015a). In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS One 10:e0126763. doi: 10.1371/journal.pone.0126763

Shastri, M. D., Stewart, N., Horne, J., Zaidi, S. T., Sohal, S. S., Peterson, G. M., et al. (2015c). Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals. PLoS One 10:e0128803. doi: 10.1371/journal.pone.0128803

Stefanidou, M. P., Ioannidou, D. J., Panayiotides, J. G., and Tosca, A. D. (1999). Low molecular weight heparin: a novel alternative therapeutic approach for lichen planus. Br. J. Dermatol. 141, 1040–1045.

Torkvist, L., Thorlacius, H., Sjoqvist, U., Bohman, L., Lapidus, A., Flood, L., et al. (1999). Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1323–1328.

Uçmak, D., Balci, G., and Harman, M. (2012). The effectiveness of treatment with enoxaparin in lichen planus. J. Clin. Exp. Invest. 3, 172–173.

Wang, L. (2011). “Heparan sulfate proteoglycan in inflammation and angiogenesis,” in Glycans in Diseases and Therapeutics, ed. S. G. M. Pavlović (Berlin: Springer), 1–29.

Weston, G., and Payette, M. (2015). Update on lichen planus and its clinical variants. Int. J. Womens Dermatol. 1, 140–149. doi: 10.1016/j.ijwd.2015.04.001

Shastri, M. D., Stewart, N., Eapen, M., Peterson, G. M., Zaidi, S. T., Gueven, N., et al. (2015a). Opposing effects of low molecular weight heparins on the release of inflammatory cytokines from peripheral blood mononuclear cells of asthmatics. PLoS One 10:e0118798. doi: 10.1371/journal.pone.0118798

Shastri, M. D., Stewart, N., Horne, J., Peterson, G. M., Gueven, N., Sohal, S. S., et al. (2015b). In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS One 10:e0126763. doi: 10.1371/journal.pone.0126763

Shastri, M. D., Stewart, N., Horne, J., Zaidi, S. T., Sohal, S. S., Peterson, G. M., et al. (2015c). Non-anticoagulant fractions of enoxaparin suppress inflammatory cytokine release from peripheral blood mononuclear cells of allergic asthmatic individuals. PLoS One 10:e0128803. doi: 10.1371/journal.pone.0128803

Stefanidou, M. P., Ioannidou, D. J., Panayiotides, J. G., and Tosca, A. D. (1999). Low molecular weight heparin: a novel alternative therapeutic approach for lichen planus. Br. J. Dermatol. 141, 1040–1045.

Torkvist, L., Thorlacius, H., Sjoqvist, U., Bohman, L., Lapidus, A., Flood, L., et al. (1999). Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1323–1328.

Uçmak, D., Balci, G., and Harman, M. (2012). The effectiveness of treatment with enoxaparin in lichen planus. J. Clin. Exp. Invest. 3, 172–173.

Wang, L. (2011). “Heparan sulfate proteoglycan in inflammation and angiogenesis,” in Glycans in Diseases and Therapeutics, ed. S. G. M. Pavlović (Berlin: Springer), 1–29.

Weston, G., and Payette, M. (2015). Update on lichen planus and its clinical variants. Int. J. Womens Dermatol. 1, 140–149. doi: 10.1016/j.ijwd.2015.04.001

Yasar, S., Serdar, Z. A., Goktay, F., Doner, N., Tanzer, C., Akkaya, D., et al. (2011). The successful treatment of palmoplantar hyperkeratotic lichen planus. Indian J. Dermatol. Venereol. Leprol. 77, 64–66.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Patel, Shastri, Ming, Zaidi and Peterson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.